



		U.S. PAT	TENT DOCUMENTS	3			
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate	
PMA	6,358,944	3/19/02	Lederman et al.	514	220		
	6,350,398	2/26/02	Breitenbach et al.	264	129		
	6,284,800	9/4/01	Broder et al.	514	652	一一一	
	6,264,917	7/24/01	Klaveness et al.	424	9.52	문문	
	6,228,864	5/8/01	Smith et al.	514	288	ENTER IT	
	6,221,368	4/24/01	Breitenbach et al.	424	400	田。	
	6,162,467	12/19/00	Miller et al.	424	468	2003 1600	
	6,150,424	11/21/00	Breitenbach et al.	514	772.5	2003 600/2900	
	6,120,802	9/19/00	Breitenbach et al.	424	464	<u> </u>	
	6,068,855	5/30/00	Leslie et al.	424	468		
	6,051,253	04/18/00	Zettler et al.	424	465		
	6,001,391	12/14/99	Zeidler et al.	424	467		
	5,980,882	11/9/99	Eichman	424	78.12		
	5,965,163	10/12/99	Miller et al.	424	468	· · · · · · · · · · · · · · · · · · ·	
	5,939,099	8/17/99	Grabowski <i>et al</i> .	424	488		
emg	5,897,910	4/27/99	Rosenberg et al.	427	2.14		
	11	FOREIGN P	ATENT DOCUMEN	TS		- 10	
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No	
MA	EP 0 463 877	1/2/92	Europe	A61K	9/54		
RMO	WO 98/26767	6/25/98	WIPO	A61K	9/50		
U	OTHER DOCUM	ENTS (Including	Author, Title, Date	, Pertinen	t Pages, Etc	.)	
PMA	Co-pending U.S. Application No. 10/225,543, filed August 22, 2002.						
RIME	Co-pending U.S. Ap	plication No. 10/2	94,693, filed Novem	ber 15, 20	02.		
PMA	Dorow et al., Effects Nonasthmatic Chror 31(2):143-7: 1986.	of Single Oral Donic Obstructive Lui	oses of Bisoprolol an ng Disease and Ang	nd Atenolol gina Pector	on Airway F is, <i>Eur</i> . J. Cli	unction in in. Pharmacol.,	

Page 1 of 2

RM Joyne

1/24/03

## INFORMATION DISCLOSURE CITATION

Atty. Docket No.	08680.0001	Appln. No.	09/488,103	To the letter of
Applicant	Paul STARK et al.			JAN 1.3 mm S
Filing Date	January 20, 2000	Group:	1615	E AND

	U.S. PATENT DOCUMENTS							
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate		
PMA	Bailliart et al., Effects of Bisoprolol on Local Vascular Resistance, Eur Heart J, 8 Suppl M:87-93: 1987							
	Haffner et al., A Metabolic Assessment of The Beta <sub>1</sub> Selectivity of Bisoprolol, <i>J. Hum. Hypertens.</i> , 6(5):397-400, 1992.							
	Horikiri <i>et al.</i> , Pharma 87(3): 289-294, 1998	lorikiri <i>et al.</i> , Pharmacokinetics and Metabolism of Bisoprolol Enantiomers in Humans, <i>J. Pharm. Sci.</i> 7(3): 289-294, 1998.						
	Janka et al., Infludence of Bisoprolol on Blood Glucose, Glucosuria, and Haemoglobin A <sub>1</sub> in Noninsuli Dependent Diabetics, J. Cardiovasc. Pharmacol, 8 Suppl 11:S96-9: 1986.							
	Kim, et al., Chiral Separation of $\beta$ -Blockers after Derivatization with (-)- $\alpha$ -Methoxy- $\alpha$ -(trifluoromethyl)phenylacetyl Chloride by Gas Chromatography, Arch. Pharm. Res., 24(5):402-6, 200							
	Kitaori, et al., CsF in Organic Synthesis. The First and Convenient Synthesis of Enantiopure Bisoprol by Use of Glycidyl Nosylate, <i>Tetrahedron Lett.</i> , 39(20), 3173-3176, 1998.							
	Klockow et al., Studies on The Receptor Profile of Bisoprolol, Arzneimittelforschung, 36(2):197-200, 1986.							
	Nandel <i>et al.</i> , Conformational Structure of Some $\beta_1$ -Blockers, Their Partitioning in Lipid and The Role Parasubstituents, <i>Ind. J. Biochem. Biophys.</i> , 32(4); 207-212, 1995.							
	Nandel <i>et al.</i> , Modeling, Design, Chiral Aspects and Role of <i>Para</i> -Substituents in Aryloxypropranolamine Based β-Blockers, <i>Ind. J. Biochem. Biophys.</i> , 36(1):29-35, 1999.							
	Schliep <i>et al.</i> , Antagonistic Effects of Bisoprolol on Several β-Adrenoceptor-Mediated Actions in Anaesthetized Cats, <i>Eur. J. Pharmacol.</i> , 123(2):253-61, 1986.							
	Schnabel et al., Binding Properties of $\beta$ -Blockers at Recobinant $\beta_1$ -, $\beta_2$ -, and $\beta_3$ -Adrenoceptors, J. Cardiovasc. Pharmacol., 36(4):466-71, 2000.							
Rmo	Wellstein et al., Reduction of Exercise Tachycardia in Man after Propranolol, Atenolol and Bisoprolo Comparison to Beta-Adrenoceptor Occupancy, Eur. Heart J., 8(Suppl. M):3-8, 1987.							
			<del></del>					

communication to applicant.

Form PTO 1449

Patent and Trademark Office - U.S. Department of Commerce